.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC25_Levilimab.Levilimab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC25_Levilimab.Levilimab| name: | Levilimab |
| ATC code: | L04AC25 | route: | subcutaneous |
| n-compartments | 2 |
Levilimab is a human monoclonal antibody targeting the interleukin-6 receptor (IL-6R), developed for the treatment of cytokine release syndrome and severe COVID-19 related pneumonia. It is approved for use in Russia for treatment of severe COVID-19 and is being investigated for other inflammatory conditions.
Pharmacokinetic parameters are estimated for healthy adult subjects based on published monoclonal antibody PK characteristics, as no peer-reviewed clinical PK study for levilimab in humans was found.